后生元(postbiotics):调节肝硬化患者肠道菌群及疾病进程的新策略
作者:
基金项目:

广东省自然科学基金重点项目(2017B030311017)


Postbiotics: a new orientation for modulation of the gut dysbiosis in liver cirrhosis
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [67]
  • |
  • 相似文献 [20]
  • | | |
  • 文章评论
    摘要:

    肝硬化是慢性肝炎发展的终末阶段,患者出现有不同程度的肠道菌群失调,并伴有肠道屏障功能的缺失和菌群移位,是引发肝硬化并发症的重要原因。尽管益生菌能在多个层面保护肠道屏障功能,但其在肝硬化肠道菌群紊乱中的疗效并不明确。现在的研究发现一些益生菌的组分或代谢产物有着与益生活菌类似的益生功效,包括稳定肠道菌群、加强肠上皮屏障功能和调节肠黏膜免疫反应等,其重要的优点是具有明确的分子结构和显著的生物活性,可能是未来调节肝硬化肠道菌群及疾病进程的新方向。本文主要总结了肝硬化肠道菌群失调对于肝硬化并发症及疾病进程的影响,探讨了益生菌的作用及局限性,并重点讨论后生元在调控肝硬化肠道菌群及疾病进程中的应用前景。

    Abstract:

    Alterations of intestinal microbiota, intestinal barrier dysfunction and bacterial translocation are the common pathogenetic characteristics in cirrhosis, which is an end-stage of liver disease resulting from different causal agents. Alterations of intestinal microbiota play an important role in induction and promotion of liver disease progression. Probiotics have been shown to exhibit limited efficacy in targeting gut barrier dysfunction caused by liver cirrhosis, while a vast studies attests to the beneficial effects of probiotics in the gut. Recently, more and more evidences suggests that certain probiotics components or metabolites (defined as "postbiotics") have beneficial properties as same as the viability status of probiotics. Postbiotics exert a variety of beneficial effects, including modulation of the microbiota composition, regulation of the epithelial barrier function and intestinal immune responses. The merits of probiotics include clear chemical structures and safety dose parameters. In this review, we introduced the effects of gut dysbiosis on complications and disease progression of cirrhosis. Specifically, discussion is focused on the prospect of postbiotics in modulation of the gut dysbiosis in cirrhosis and its potential role in improve the disease progression.

    参考文献
    [1] Long B, Koyfman A. The emergency medicine evaluation and management of the patient with cirrhosis. The American Journal of Emergency Medicine, 2018, 36(4):689-698.
    [2] Olson JC. Intensive care management of patients with cirrhosis. Current Treatment Options in Gastroenterology, 2018, 16(2):241-252.
    [3] Yu SL, Gong YL, Shao RT, Wu GY. Study on burden of diseases of chronic hepatitis B, virrhosis and liver cancer caused by hepatitis B virus. China Public Health, 2003, 19(3):280-282. (in Chinese)于淑丽, 龚幼龙, 邵瑞太, 武桂英. 慢性乙肝、乙肝后肝硬化和肝癌的疾病负担. 中国公共卫生, 2003, 19(3):280-282.
    [4] Piano S, Brocca A, Mareso S, Angeli P. Infections complicating cirrhosis. Liver International:Official Journal of the International Association for the Study of the Liver, 2018, 38 Suppl 1:126-133.
    [5] Macnaughtan J, Jalan R. Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis. The American Journal of Gastroenterology, 2015, 110(10):1399-1410.
    [6] Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. Journal of Hepatology, 2006, 45(5):744-757.
    [7] Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. Journal of Hepatology, 2014, 60(5):940-947.
    [8] Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction:Distinctive features and clinical relevance. Journal of Hepatology, 2014, 61(6):1385-1396.
    [9] Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, Tseng SC, Lin WP, Chen WT, Sheen IS. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. Journal of Hepatology, 2007, 46(5):816-826.
    [10] Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, Gillevet PM. Linkage of gut microbiome with cognition in hepatic encephalopathy. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2012, 302(1):G168-G175.
    [11] Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. The New England Journal of Medicine, 2010, 362(12):1140-1142.
    [12] Fukui H. Gut microbiome-based therapeutics in liver cirrhosis:Basic consideration for the next step. Journal of Clinical and Translational Hepatology, 2017, 5(3):249-260.
    [13] Cavallari JF, Fullerton MD, Duggan BM, Foley KP, Denou E, Smith BK, Desjardins EM, Henriksbo BD, Kim KJ, Tuinema BR, Stearns JC, Prescott D, Rosenstiel P, Coombes BK, Steinberg GR, Schertzer JD. Muramyl dipeptide-based postbiotics mitigate obesity-induced insulin resistance via IRF4. Cell Metabolism, 2017, 25(5):1063-1074.e3.
    [14] Tsilingiri K, Barbosa T, Penna G, Caprioli F, Sonzogni A, Viale G, Rescigno M. Probiotic and postbiotic activity in health and disease:comparison on a novel polarised ex-vivo organ culture model. Gut, 2012, 61(7):1007-1015.
    [15] Chen YF, Yang FL, Lu HF, Wang BH, Chen YB, Lei DJ, Wang YZ, Zhu BL, Li LJ. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology, 2011, 54(2):562-572.
    [16] Qin N, Yang FL, Li A, Prifti E, Chen YF, Shao L, Guo J, Le Chatelier E, Yao J, Wu LJ, Zhou JW, Ni SJ, Liu L, Pons N, Batto JM, Kennedy SP, Leonard P, Yuan CH, Ding WC, Chen YT, Hu XJ, Zheng BW, Qian GR, Xu W, Ehrlich SD, Zheng SS, Li LJ. Alterations of the human gut microbiome in liver cirrhosis. Nature, 2014, 513(7516):59-64.
    [17] Macnaughtan J, Davies N, Stadlbauer V, Damink SWO, Mookerjee RP, Jalan R. Evidence for compartmentalised endotoxemia and its effect on neutrophil function in the portal circulation in cirrhosis. Meeting of the American Association for the Study of Liver Diseases, 2010, 52(4):342A-343A.
    [18] Mookerjee RP, Stadlbauer V, Lidder S, Wright GAK, Hodges SJ, Davies NA, Jalan R. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology, 2007, 46(3):831-840.
    [19] Hackstein CP, Assmus LM, Welz M, Klein S, Schwandt T, Schultze J, Förster I, Gondorf F, Beyer M, Kroy D, Kurts C, Trebicka J, Kastenmüller W, Knolle PA, Abdullah Z. Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis. Gut, 2017, 66(3):507-518.
    [20] Chen YF, Guo J, Qian GR, Fang DQ, Shi D, Guo LH, Li LJ. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. Journal of Gastroenterology and Hepatology, 2015, 30(9):1429-1437.
    [21] Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology, 2010, 51(3):1062-1069.
    [22] Butterworth RF. The liver-brain axis in liver failure:neuroinflammation and encephalopathy. Nature Reviews Gastroenterology & Hepatology, 2013, 10(9):522-528.
    [23] Dhiman RK, Sawhney IMS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Digestive Diseases and Sciences, 2000, 45(8):1549-1552.
    [24] Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One, 2013, 8(4):e60042.
    [25] Alexopoulou A, Papadopoulos N, Eliopoulos DG, Alexaki A, Tsiriga A, Toutouza M, Pectasides D. Increasing frequency of Gram-positive cocci and Gram-negative multidrug-resistant bacteria in spontaneous bacterial peritonitis. Liver International, 2013, 33(7):975-981.
    [26] Fernãndez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology, 2007, 133(3):818-824.
    [27] Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, Rolston DDK, Sferra TJ, Hernandez AV. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients:A meta-analysis. Journal of Gastroenterology and Hepatology, 2013, 28(2):235-242.
    [28] Kwon JH, Koh SJ, Kim W, Jung YJ, Kim JW, Kim BG, Lee KL, Im JP, Kim YJ, Kim JS, Yoon JH, Lee HS, Jung HC. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. Journal of Gastroenterology and Hepatology, 2014, 29(4):775-781.
    [29] Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis:A randomized controlled trial. Clinical Gastroenterology and Hepatology, 2014, 12(6):1003-1008.e1.
    [30] Rincón D, Vaquero J, Hernando A, Galindo E, Ripoll C, Puerto M, Salcedo M, Francés R, Matilla A, Catalina MV, Clemente G, Such J, Bañares R. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver International, 2014, 34(10):1504-1512.
    [31] Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora:effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology, 2004, 39(5):1441-1449.
    [32] Saji S, Kumar S, Thomas V. A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Tropical Gastroenterology:Official Journal of the Digestive Diseases Foundation, 2011, 32(2):128-132.
    [33] Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, Bengmark S, Neuhaus P. Supply of pre-and probiotics reduces bacterial infection rates after liver transplantation-a randomized, double-blind trial. American Journal of Transplantation, 2005, 5(1):125-130.
    [34] Sherid M, Samo S, Sulaiman S, Husein H, Sifuentes H, Sridhar S. Liver abscess and bacteremia caused by lactobacillus:role of probiotics? Case report and review of the literature. Bmc Gastroenterology, 2016, 16:138.
    [35] Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG. Probiotic prophylaxis in predicted severe acute pancreatitis:a randomised, double-blind, placebo-controlled trial. Lancet (London, England), 2008, 371(9613):651-659.
    [36] Lebeer S, Bron PA, Marco ML, van Pijkeren JP, O'Connell Motherway M, Hill C, Pot B, Roos S, Klaenhammer T. Identification of probiotic effector molecules:present state and future perspectives. Current Opinion in Biotechnology, 2017, 49:217-223.
    [37] Aguilar-Toalá JE, Garcia-Varela R, Garcia HS, Mata-Haro V, González-Córdova AF, Vallejo-Cordoba B, Hernández-Mendoza A. Postbiotics:An evolving term within the functional foods field. Trends in Food Science & Technology, 2018, 75:105-114.
    [38] Shenderov BA. Metabiotics:novel idea or natural development of probiotic conception. Microbial Ecology in Health & Disease, 2013, 24:20399.
    [39] Sahadeva RPK, Leong SF, Chua KH, Tan CH, Chan HY, Tong EV, Wong SY, Chan HK. Survival of commercial probiotic strains to pH and bile. International Food Research Journal, 2011, 18(4):1515-1522.
    [40] Kareem KY, Ling FH, Chwen LT, Foong OM, Asmara SA. Inhibitory activity of postbiotic produced by strains of Lactobacillus plantarum using reconstituted media supplemented with inulin. Gut Pathogens, 2014, 6(1):23.
    [41] Yu J, Wang WH, Menghe BLG, Jiri MT, Wang HM, Liu WJ, Bao QH, Lu Q, Zhang JC, Wang F, Xu HY, Sun TS, Zhang HP. Diversity of lactic acid bacteria associated with traditional fermented dairy products in Mongolia. Journal of Dairy Science, 2011, 94(7):3229-3241.
    [42] Turner DL, Lamosa P, Rodríguez A, Martínez B. Structure and properties of the metastable bacteriocin Lcn972 from Lactococcus lactis. Journal of Molecular Structure, 2013, 1031:207-210.
    [43] Sassone-Corsi M, Nuccio SP, Liu H, Hernandez D, Vu CT, Takahashi AA, Edwards RA, Raffatellu M. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature, 2016, 540(7632):280-283.
    [44] Levy M, Thaiss CA, Zeevi D, Dohnalová L, Zilberman-Schapira G, Mahdi JA, David E, Savidor A, Korem T, Herzig Y, Pevsner-Fischer M, Shapiro H, Christ A, Harmelin A, Halpern Z, Latz E, Flavell RA, Amit I, Segal E, Elinav E,. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell, 2015, 163(6):1428-1443.
    [45] He XL, Zeng Q, Puthiyakunnon S, Zeng ZJ, Yang WJ, Qiu JW, Du L, Boddu S, Wu TW, Cai DX, Huang SH, Cao H. Lactobacillus rhamnosus GG supernatant enhance neonatal resistance to systemic Escherichia coli K1 infection by accelerating development of intestinal defense. Scientific Reports, 2017, 7:43305.
    [46] Yan F, Liu LP, Dempsey PJ, Tsai YH, Raines EW, Wilson CL, Cao HL, Cao Z, Liu LS, Polk DB. A Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth factor receptor. The Journal of Biological Chemistry, 2013, 288(42):30742-30751.
    [47] Pelaseyed T, Bergström JH, Gustafsson JK, Ermund A, Birchenough GMH, Schütte A, van der Post S, Svensson F, Rodríguez-Piñeiro AM, Nyström EEL, Wising C, Johansson MEV, Hansson GC. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunological Reviews, 2014, 260(1):8-20.
    [48] Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunology, 2008, 1(1):11-22.
    [49] Möndel M, Schroeder BO, Zimmermann K, Huber H, Nuding S, Beisner J, Fellermann K, Stange EF, Wehkamp J. Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans. Mucosal Immunology, 2008, 2(2):166-172.
    [50] Yoda K, Miyazawa K, Hosoda M, Hiramatsu M, Yan F, He F. Lactobacillus GG-fermented milk prevents DSS-induced colitis and regulates intestinal epithelial homeostasis through activation of epidermal growth factor receptor. European Journal of Nutrition, 2014, 53(1):105-115.
    [51] Yan F, Cao HW, Cover TL, Washington MK, Shi Y, Liu LS, Chaturvedi R, Peek RM Jr, Wilson KT, Polk DB. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. The Journal of Clinical Investigation, 2011, 121(6):2242-2253.
    [52] Corridoni D, Pastorelli L, Mattioli B, Locovei S, Ishikawa D, Arseneau KO, Chieppa M, Cominelli F, Pizarro TT. Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanism. PLoS One, 2012, 7(7):e42067.
    [53] Wang YH, Kirpich I, Liu YL, Ma ZH, Barve S, McClain CJ, Feng WK. Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. The American Journal of Pathology, 2011, 179(6):2866-2875.
    [54] Wang YH, Liu YL, Sidhu A, Ma ZH, McClain C, Feng WK. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2012, 303(1):G32-G41.
    [55] Prisciandaro LD, Geier MS, Chua AE, Butler RN, Cummins AG, Sander GR, Howarth GS. Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage. Supportive Care in Cancer, 2012, 20(12):3205-3210.
    [56] von Schillde MA, Hörmannsperger G, Weiher M, Alpert CA, Hahne H, Bäuerl C, van Huynegem K, Steidler L, Hrncir T, Pérez-Martínez G, Kuster B, Haller D. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host & Microbe, 2012, 11(4):387-396.
    [57] Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature, 2008, 453(7195):620-625.
    [58] Ménard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut, 2004, 53(6):821-828.
    [59] Hoarau C, Lagaraine C, Martin L, Velge-Roussel F, Lebranchu Y. Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. Journal of Allergy and Clinical Immunology, 2006, 117(3):696-702.
    [60] Hoarau C, Martin L, Faugaret D, Baron C, Dauba A, Aubert-Jacquin C, Velge-Roussel F, Lebranchu Y. Supernatant from Bifidobacterium differentially modulates transduction signaling pathways for biological functions of human dendritic cells. PLoS One, 2008, 3(7):e2753.
    [61] Xu RH, Shang N, Li PL. In vitro and in vivo antioxidant activity of exopolysaccharide fractions from Bifidobacterium animalis RH. Anaerobe, 2011, 17(5):226-231.
    [62] Li W, Ji J, Chen XH, Jiang M, Rui X, Dong MS. Structural elucidation and antioxidant activities of exopolysaccharides from Lactobacillus helveticus MB2-1. Carbohydrate Polymers, 2014, 102:351-359.
    [63] Lebeer S, Claes IJJ, Vanderleyden J. Anti-inflammatory potential of probiotics:lipoteichoic acid makes a difference. Trends in Microbiology, 2012, 20(1):5-10.
    [64] Dinić M, Lukić J, Djokić J, Milenković M, Strahinić I, Golić N, Begović J. Lactobacillus fermentum postbiotic-induced autophagy as potential approach for treatment of acetaminophen hepatotoxicity. Frontiers in Microbiology, 2017, 8:594.
    [65] Sharma M, Shukla G. Metabiotics:One step ahead of probiotics; an insight into mechanisms involved in anticancerous effect in colorectal cancer. Frontiers in Microbiology, 2016, 7:1940.
    [66] Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(43):16731-16736.
    [67] Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan JG. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Scientific Reports, 2017, 7(1):1529.
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

高杰,何肖龙,曹虹. 后生元(postbiotics):调节肝硬化患者肠道菌群及疾病进程的新策略[J]. 微生物学报, 2018, 58(11): 1938-1949

复制
相关视频

分享
文章指标
  • 点击次数:1407
  • 下载次数: 2826
  • HTML阅读次数: 6646
  • 引用次数: 0
历史
  • 收稿日期:2018-05-01
  • 最后修改日期:2018-06-29
  • 在线发布日期: 2018-11-06
文章二维码